New stainless steel access interlock prevents accidental lock-in in dangerous areas

Published: 16-Apr-2010
Manufacturing Regulatory

SERV Trayvou Interverrouillage (STI) has launched the NXO1LTC, a new access interlock with personnel key for harsh or corrosive environments

SERV Trayvou Interverrouillage (STI) has launched the NXO1LTC, a new access interlock with personnel key for harsh or corrosive environments. It consists of a lock with two key slots that work on a free key/trapped key basis.

To gain access to a dangerous area, the operator has to first insert an isolation key into the lock portion. Turning this key releases the personnel key, and allows the bolt to be removed and the door opened.

The operator retains the personnel key while inside the dangerous area. This prevents the door being shut behind them and also stops the machine from being restarted by another person.

The NXO1LTC’s completely stainless steel construction makes it suitable for use in harsh or corrosive environments as the paper, food, robotic, chemical and petrochemical industries.

As an entirely mechanical proposition, the NXO1LTC removes the need for cabling, reducing related maintenance costs and eliminating the risk of a cable malfunction.

STI’s safety products are heavy-duty and comply with all European machinery directives currently in force. They are popular with customers due to their strength and simple method of operation.
See more

You may also like

Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

Read more
New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
  3. FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
  4. Simplifying continuous operations: lowering the barrier to faster development Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus

AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Subscribe now